Direct quality control of glycoengineered erythropoietin variants
Several therapeutics are glycosylated proteins, yet the analysis of their specific glycosylation patterns remains challenging. Here the authors demonstrate an approach for the detailed characterization of glycosylated biopharmaceuticals applied to the determination of the glycoproteoform profile of...
Guardado en:
Autores principales: | Tomislav Čaval, Weihua Tian, Zhang Yang, Henrik Clausen, Albert J. R. Heck |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6d591091bbd4425594268aada88a4112 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
por: Hanne L. P. Tytgat, et al.
Publicado: (2019) -
Characteristics of erythropoietin antibodies in patients treated with recombinant human erythropoietin
por: A. M. Kudryashova, et al.
Publicado: (2020) -
The use of erythropoietins in oncology
por: Liliya E. Ziganshina, et al.
Publicado: (2021) -
A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
por: Christian M. Harding, et al.
Publicado: (2019) -
Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
por: Cassandra L. Pegg, et al.
Publicado: (2017)